Business
Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers
About this update from Cerus Corporation
[{"type":"text","content":" CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus’ entire INTERCEPT product line. Under this agreement, Cerus will partner with BCA to drive expanded access to pathogen reduction technology for platelets, plasma and pathogen reduced cryoprecipitated fibrinogen complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, across their blood center membership.\n\n“We are excited to partner with BCA and the 60+ independent community blood centers they represent. This agreement demonstrates our shared commitment to drive innovation and expand access to safer blood products,” said Vivek Jayaraman, Cerus’ chief operating officer. “We believe leveraging BCA’s resource sharing model will enable us to rapidly expand IFC adoption. Furthermore, this agreement provides access to pathogen-reduced platelets for new customers at both the blood center and hospital. I believe this agreement has the potential to be quite positive for BCA, their blood center membership and Cerus.”\n\n“We appreciate the opportunity to collaborate with Cerus. We have a shared commitment to bringing innovation to the transfusion medicine market and are looking forward to a mutually rewarding partnership,” said Bill Block, BCA’s president and chief executive officer. “We believe pathogen inactivation is an important technology in blood safety and are pleased to be working with Cerus to expand availability within our membership.”\n\nUnder the terms of the agreement, ongoing production of IFC at BCA member blood centers will move under a resource-sharing model. This structure is designed to facilitate easier access to, and distribution of IFC across all BCA member blood centers and to their hospital customers. Through collaborative training and education initiatives, Cerus and BCA believe these efforts will expand awareness and adoption of pathogen reduction technologies.\n\nABOUT CERUS\n\nCerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, Califo...